Preclinical models demonstrated that, after Ad-TK + Ad-Flt3L treatment, DC are activated by damage-associated molecular pattern molecules as HMGB1 and after uptake of tumor antigens from dying cells they prime a systemic immune response [162]. The gene discussed is FLT3LG; the disease is neoplasm.